{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:48:08Z","timestamp":1789501688497,"version":"build-2803163510"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2013,10,8]],"date-time":"2013-10-08T00:00:00Z","timestamp":1381190400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1038\/nrneph.2013.182","type":"journal-article","created":{"date-parts":[[2013,10,8]],"date-time":"2013-10-08T05:37:17Z","timestamp":1381210637000},"page":"681-692","source":"Crossref","is-referenced-by-count":33,"title":["Therapy for patients with CKD and low bone mineral density"],"prefix":"10.1038","volume":"9","author":[{"given":"Susan M.","family":"Ott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,10,8]]},"reference":[{"key":"BFnrneph2013182_CR1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.7326\/0003-4819-64-2-293","volume":"64","author":"JP Pendras","year":"1966","unstructured":"Pendras, J. P. & Erickson, R. V. Hemodialysis: a successful therapy for chronic uremia. Ann. Intern. Med. 64, 293\u2013311 (1966).","journal-title":"Ann. Intern. Med."},{"key":"BFnrneph2013182_CR2","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1359\/jbmr.080610","volume":"23","author":"A Fahrleitner-Pammer","year":"2008","unstructured":"Fahrleitner-Pammer, A. et al. Bone markers predict cardiovascular events in chronic kidney disease. J. Bone Miner. Res. 23, 1850\u20131858 (2008).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrneph2013182_CR3","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1046\/j.1523-1755.2000.00178.x","volume":"58","author":"AM Alem","year":"2000","unstructured":"Alem, A. M. et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int. 58, 396\u2013399 (2000).","journal-title":"Kidney Int."},{"key":"BFnrneph2013182_CR4","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.bone.2006.09.017","volume":"40","author":"C Mitterbauer","year":"2007","unstructured":"Mitterbauer, C., Kramar, R. & Oberbauer, R. Age and sex are sufficient for predicting fractures occurring within 1 year of hemodialysis treatment. Bone 40, 516\u2013521 (2007).","journal-title":"Bone"},{"key":"BFnrneph2013182_CR5","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1007\/s00198-006-0133-y","volume":"17","author":"SA Jamal","year":"2006","unstructured":"Jamal, S. A., Leiter, R. E., Jassal, V., Hamilton, C. J. & Bauer, D. C. Impaired muscle strength is associated with fractures in hemodialysis patients. Osteoporos. Int. 17, 1390\u20131397 (2006).","journal-title":"Osteoporos. Int."},{"key":"BFnrneph2013182_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1053\/j.ajkd.2007.08.019","volume":"51","author":"AC Dooley","year":"2008","unstructured":"Dooley, A. C., Weiss, N. S. & Kestenbaum, B. Increased risk of hip fracture among men with CKD. Am. J. Kidney Dis. 51, 38\u201344 (2008).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2013182_CR7","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s00198-005-1903-7","volume":"16","author":"L Dukas","year":"2005","unstructured":"Dukas, L., Schacht, E. & Stahelin, H. B. In elderly men and women treated for osteoporosis a low creatinine clearance of <65 ml\/min is a risk factor for falls and fractures. Osteoporos. Int. 16, 1683\u20131690 (2005).","journal-title":"Osteoporos. Int."},{"key":"BFnrneph2013182_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1001\/archinte.167.2.133","volume":"167","author":"KE Ensrud","year":"2007","unstructured":"Ensrud, K. E. et al. Renal function and risk of hip and vertebral fractures in older women. Arch. Intern. Med. 167, 133\u2013139 (2007).","journal-title":"Arch. Intern. Med."},{"key":"BFnrneph2013182_CR9","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1111\/j.1532-5415.2008.01807.x","volume":"56","author":"AZ LaCroix","year":"2008","unstructured":"LaCroix, A. Z. et al. Cystatin-C, renal function and incidence of hip fracture in postmenopausal women. J. Am. Soc. Geriat. 56, 1434\u20131441 (2008).","journal-title":"J. Am. Soc. Geriat."},{"key":"BFnrneph2013182_CR10","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1002\/jbmr.309","volume":"26","author":"HH Malluche","year":"2011","unstructured":"Malluche, H. H., Mawad, H. W. & Monier-Faugere, M. C. Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J. Bone Miner. Res. 26, 1368\u20131376 (2011).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrneph2013182_CR11","doi-asserted-by":"publisher","first-page":"877","DOI":"10.2215\/CJN.06550810","volume":"6","author":"D Cejka","year":"2011","unstructured":"Cejka, D. et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin. J. Am. Soc. Nephrol. 6, 877\u2013882 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"BFnrneph2013182_CR12","doi-asserted-by":"publisher","first-page":"F882","DOI":"10.1152\/ajprenal.00360.2010","volume":"299","author":"V Lavi-Moshayoff","year":"2010","unstructured":"Lavi-Moshayoff, V., Wasserman, G., Meir, T., Silver, J. & Naveh-Many, T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am. J. Physiol. Renal Physiol. 299, F882\u2013F889 (2010).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"BFnrneph2013182_CR13","unstructured":"KDIGO. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD\u2013MBD). Kidney Int. Suppl. 113, S1\u2013S130 (2009)."},{"key":"BFnrneph2013182_CR14","doi-asserted-by":"crossref","unstructured":"Evolve Investigators. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N. Engl. J. Med. 367, 2482\u20132494 (2012).","DOI":"10.1056\/NEJMoa1205624"},{"key":"BFnrneph2013182_CR15","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s00198-003-1435-y","volume":"14","author":"S Klawansky","year":"2003","unstructured":"Klawansky, S. et al. Relationship between age, renal function and bone mineral density in the US population. Osteoporos. Int. 14, 570\u2013576 (2003).","journal-title":"Osteoporos. Int."},{"key":"BFnrneph2013182_CR16","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1046\/j.1523-1755.2002.00306.x","volume":"61","author":"CY Hsu","year":"2002","unstructured":"Hsu, C. Y., Cummings, S. R., McCulloch, C. E. & Chertow, G. M. Bone mineral density is not diminished by mild to moderate chronic renal insufficiency. Kidney Int. 61, 1814\u20131820 (2002).","journal-title":"Kidney Int."},{"key":"BFnrneph2013182_CR17","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/j.1440-1797.2009.01159.x","volume":"14","author":"SM Ott","year":"2009","unstructured":"Ott, S. M. Review article: bone density in patients with chronic kidney disease stages 4\u20135 Nephrology (Carlton) 14, 395\u2013403 (2009).","journal-title":"Nephrology (Carlton)"},{"key":"BFnrneph2013182_CR18","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1359\/JBMR.050817","volume":"20","author":"PD Miller","year":"2005","unstructured":"Miller, P. D. et al. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J. Bone Miner. Res. 20, 2105\u20132115 (2005).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrneph2013182_CR19","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1359\/jbmr.070112","volume":"22","author":"SA Jamal","year":"2007","unstructured":"Jamal, S. A. et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the Fracture Intervention Trial. J. Bone Miner. Res. 22, 503\u2013508 (2007).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrneph2013182_CR20","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1681\/ASN.2007050555","volume":"19","author":"A Ishani","year":"2008","unstructured":"Ishani, A., Blackwell, T., Jamal, S. A., Cummings, S. R. & Ensrud, K. E. The effect of raloxifene treatment in postmenopausal women with CKD. J. Am. Soc. Nephrol. 19, 1430\u20131438 (2008).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2013182_CR21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00198-006-0189-8","volume":"18","author":"PD Miller","year":"2007","unstructured":"Miller, P. D., Schwartz, E. N., Chen, P., Misurski, D. A. & Krege, J. H. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos. Int. 18, 59\u201368 (2007).","journal-title":"Osteoporos. Int."},{"key":"BFnrneph2013182_CR22","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","volume":"291","author":"GL Anderson","year":"2004","unstructured":"Anderson, G. L. et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291, 1701\u20131712 (2004).","journal-title":"JAMA"},{"key":"BFnrneph2013182_CR23","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"JE Rossouw","year":"2002","unstructured":"Rossouw, J. E. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288, 321\u2013333 (2002).","journal-title":"JAMA"},{"key":"BFnrneph2013182_CR24","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1056\/NEJMoa071513","volume":"356","author":"JE Manson","year":"2007","unstructured":"Manson, J. E. et al. Estrogen therapy and coronary-artery calcification. N. Engl. J. Med. 356, 2591\u20132602 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2013182_CR25","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1093\/ndt\/14.5.1238","volume":"14","author":"J Matuszkiewicz-Rowinska","year":"1999","unstructured":"Matuszkiewicz-Rowinska, J. et al. The benefits of hormone replacement therapy in pre-menopausal women with oestrogen deficiency on haemodialysis. Nephrol. Dial. Transplant. 14, 1238\u20131243 (1999).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2013182_CR26","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1046\/j.1523-1755.2003.00073.x","volume":"64","author":"C Stehman-Breen","year":"2003","unstructured":"Stehman-Breen, C., Anderson, G., Gibson, D., Kausz, A. T. & Ott, S. Pharmacokinetics of oral micronized beta-estradiol in postmenopausal women receiving maintenance hemodialysis. Kidney Int. 64, 290\u2013294 (2003).","journal-title":"Kidney Int."},{"key":"BFnrneph2013182_CR27","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1136\/pgmj.2006.045963","volume":"82","author":"F Albaaj","year":"2006","unstructured":"Albaaj, F. et al. Prevalence of hypogonadism in male patients with renal failure. Postgrad. Med. J. 82, 693\u2013696 (2006).","journal-title":"Postgrad. Med. J."},{"key":"BFnrneph2013182_CR28","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/0026-0495(69)90024-9","volume":"18","author":"A Guevara","year":"1969","unstructured":"Guevara, A. et al. Serum gonadotropin and testosterone levels in uremic males undergoing intermittent dialysis. Metabolism 18, 1062\u20131066 (1969).","journal-title":"Metabolism"},{"key":"BFnrneph2013182_CR29","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1359\/jbmr.2002.17.2.341","volume":"17","author":"SM Ott","year":"2002","unstructured":"Ott, S. M., Oleksik, A., Lu, Y., Harper, K. & Lips, P. Bone histomorphometric and biochemical marker results of a 2-year placebo-controlled trial of raloxifene in postmenopausal women. J. Bone Miner. Res. 17, 341\u2013348 (2002).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrneph2013182_CR30","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","volume":"281","author":"SR Cummings","year":"1999","unstructured":"Cummings, S. R. et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281, 2189\u20132197 (1999).","journal-title":"JAMA"},{"key":"BFnrneph2013182_CR31","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1359\/jbmr.2001.16.1.189","volume":"16","author":"JR Zanchetta","year":"2001","unstructured":"Zanchetta, J. R. & Bogado, C. E. Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism. J. Bone Miner. Res. 16, 189\u2013190 (2001).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrneph2013182_CR32","doi-asserted-by":"publisher","first-page":"423","DOI":"10.5414\/CNP72423","volume":"72","author":"R Eriguchi","year":"2009","unstructured":"Eriguchi, R., Umakoshi, J., Miura, S. & Sato, Y. Raloxifene ameliorates progressive bone loss in postmenopausal dialysis patients with controlled parathyroid hormone levels. Clin. Nephrol. 72, 423\u2013429 (2009).","journal-title":"Clin. Nephrol."},{"key":"BFnrneph2013182_CR33","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/ki.2010.378","volume":"79","author":"ML Melamed","year":"2011","unstructured":"Melamed, M. L. et al. Raloxifene, a selective estrogen receptor modulator, is renoprotective: a post-hoc analysis. Kidney Int. 79, 241\u2013249 (2011).","journal-title":"Kidney Int."},{"key":"BFnrneph2013182_CR34","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1046\/j.1523-1755.2003.00005.x","volume":"63","author":"E Hernandez","year":"2003","unstructured":"Hernandez, E. et al. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney Int. 63, 2269\u20132274 (2003).","journal-title":"Kidney Int."},{"issue":"Suppl. 1","key":"BFnrneph2013182_CR35","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1744-9987.2011.00929.x","volume":"15","author":"M Tanaka","year":"2011","unstructured":"Tanaka, M. et al. Effects of raloxifene on bone mineral metabolism in postmenopausal Japanese women on hemodialysis. Ther. Apher. Dial. 15 (Suppl. 1), 62\u201366 (2011).","journal-title":"Ther. Apher. Dial."},{"key":"BFnrneph2013182_CR36","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1016\/j.amjmed.2008.12.003","volume":"122","author":"JP Bilezikian","year":"2009","unstructured":"Bilezikian, J. P. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am. J. Med. 122, S14\u2013S21 (2009).","journal-title":"Am. J. Med."},{"key":"BFnrneph2013182_CR37","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1172\/JCI119668","volume":"100","author":"PM Chavassieux","year":"1997","unstructured":"Chavassieux, P. M. et al. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J. Clin. Invest. 100, 1475\u20131480 (1997).","journal-title":"J. Clin. Invest."},{"key":"BFnrneph2013182_CR38","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S8756-3282(02)00869-4","volume":"31","author":"EF Eriksen","year":"2002","unstructured":"Eriksen, E. F., Melsen, F., Sod, E., Barton, I. & Chines, A. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 31, 620\u2013625 (2002).","journal-title":"Bone"},{"key":"BFnrneph2013182_CR39","first-page":"538","volume":"2","author":"G Boivin","year":"2002","unstructured":"Boivin, G. & Meunier, P. J. Effects of bisphosphonates on matrix mineralization. J. Musculoskelet. Neuronal. Interact. 2, 538\u2013543 (2002).","journal-title":"J. Musculoskelet. Neuronal. Interact."},{"key":"BFnrneph2013182_CR40","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.bone.2006.01.161","volume":"39","author":"B Borah","year":"2006","unstructured":"Borah, B. et al. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone 39, 345\u2013352 (2006).","journal-title":"Bone"},{"key":"BFnrneph2013182_CR41","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1359\/JBMR.051018","volume":"21","author":"DC Bauer","year":"2006","unstructured":"Bauer, D. C. et al. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J. Bone Miner. Res. 21, 292\u2013299 (2006).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrneph2013182_CR42","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1056\/NEJMoa1106173","volume":"366","author":"MP Whyte","year":"2012","unstructured":"Whyte, M. P. et al. Enzyme-replacement therapy in life-threatening hypophosphatasia. N. Engl. J. Med. 366, 904\u2013913 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2013182_CR43","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","volume":"19","author":"RG Russell","year":"2008","unstructured":"Russell, R. G., Watts, N. B., Ebetino, F. H. & Rogers, M. J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos. Int. 19, 733\u2013759 (2008).","journal-title":"Osteoporos. Int."},{"key":"BFnrneph2013182_CR44","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1136\/bmj.292.6530.1227","volume":"292","author":"CJ Gibbs","year":"1986","unstructured":"Gibbs, C. J., Aaron, J. E. & Peacock, M. Osteomalacia in Paget's disease treated with short term, high dose sodium etidronate. Br. Med. J. (Clin. Res. Ed.) 292, 1227\u20131229 (1986).","journal-title":"Br. Med. J. (Clin. Res. Ed.)"},{"key":"BFnrneph2013182_CR45","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/jbmr.1752","volume":"28","author":"JE Otero","year":"2013","unstructured":"Otero, J. E. et al. Severe skeletal toxicity from protracted etidronate therapy for generalized arterial calcification of infancy. J. Bone Miner. Res. 28, 419\u2013430 (2013).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrneph2013182_CR46","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1359\/jbmr.070906","volume":"23","author":"RR Recker","year":"2008","unstructured":"Recker, R. R. et al. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J. Bone Miner. Res. 23, 6\u201316 (2008).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrneph2013182_CR47","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1002\/jbmr.1719","volume":"27","author":"RM Dell","year":"2012","unstructured":"Dell, R. M. et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J. Bone Miner. Res. 27, 2544\u20132550 (2012).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrneph2013182_CR48","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/sj.ki.5000311","volume":"69","author":"FC Barreto","year":"2006","unstructured":"Barreto, F. C. et al. Osteoporosis in hemodialysis patients revisited by bone histomorphometry: a new insight into an old problem. Kidney Int. 69, 1852\u20131857 (2006).","journal-title":"Kidney Int."},{"key":"BFnrneph2013182_CR49","doi-asserted-by":"publisher","unstructured":"Chavassieux, P. et al. Bone histomorphometry of transiliac paired bone biopsies after 6 or 12 months of treatment with oral strontium ranelate in 387 osteoporotic women. Randomized comparison to alendronate. J. Bone Miner. Res. http:\/\/dx.doi.org\/10.1002\/jbmr.2074 .","DOI":"10.1002\/jbmr.2074"},{"key":"BFnrneph2013182_CR50","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1038\/ki.2008.356","volume":"74","author":"MA Perazella","year":"2008","unstructured":"Perazella, M. A. & Markowitz, G. S. Bisphosphonate nephrotoxicity. Kidney Int. 74, 1385\u20131393 (2008).","journal-title":"Kidney Int."},{"key":"BFnrneph2013182_CR51","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","volume":"18","author":"JH Lin","year":"1996","unstructured":"Lin, J. H. Bisphosphonates: a review of their pharmacokinetic properties. Bone 18, 75\u201385 (1996).","journal-title":"Bone"},{"key":"BFnrneph2013182_CR52","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/j.1440-1797.2006.00569.x","volume":"11","author":"M Buttazzoni","year":"2006","unstructured":"Buttazzoni, M. et al. Elimination and clearance of pamidronate by haemodialysis. Nephrology (Carlton) 11, 197\u2013200 (2006).","journal-title":"Nephrology (Carlton)"},{"key":"BFnrneph2013182_CR53","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1159\/000276666","volume":"29","author":"R Amerling","year":"2010","unstructured":"Amerling, R., Harbord, N. B., Pullman, J. & Feinfeld, D. A. Bisphosphonate use in chronic kidney disease: association with adynamic bone disease in a bone histology series. Blood Purif. 29, 293\u2013299 (2010).","journal-title":"Blood Purif."},{"key":"BFnrneph2013182_CR54","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1053\/j.ajkd.2003.08.023","volume":"42","author":"KC Lu","year":"2003","unstructured":"Lu, K. C., Yeung, L. K., Lin, S. H., Lin, Y. F. & Chu, P. Acute effect of pamidronate on PTH secretion in postmenopausal hemodialysis patients with secondary hyperparathyroidism. Am. J. Kidney Dis. 42, 1221\u20131227 (2003).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2013182_CR55","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.1046\/j.1523-1755.63.s85.21.x","volume":"85","author":"JV Torregrosa","year":"2003","unstructured":"Torregrosa, J. V., Moreno, A., Mas, M., Ybarra, J. & Fuster, D. Usefulness of pamidronate in severe secondary hyperparathyroidism in patients undergoing hemodialysis. Kidney Int. Suppl. 85, S88\u2013S90 (2003).","journal-title":"Kidney Int. Suppl."},{"key":"BFnrneph2013182_CR56","first-page":"510","volume":"21","author":"R Bergner","year":"2008","unstructured":"Bergner, R. et al. Treatment of reduced bone density with ibandronate in dialysis patients. J. Nephrol. 21, 510\u2013516 (2008).","journal-title":"J. Nephrol."},{"key":"BFnrneph2013182_CR57","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000341864","volume":"36","author":"E Mitsopoulos","year":"2012","unstructured":"Mitsopoulos, E. et al. Impact of long-term cinacalcet, ibandronate or teriparatide therapy on bone mineral density of hemodialysis patients: a pilot study. Am. J. Nephrol. 36, 238\u2013244 (2012).","journal-title":"Am. J. Nephrol."},{"key":"BFnrneph2013182_CR58","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1053\/j.ajkd.2009.12.039","volume":"56","author":"ND Toussaint","year":"2010","unstructured":"Toussaint, N. D., Lau, K. K., Strauss, B. J., Polkinghorne, K. R. & Kerr, P. G. Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am. J. Kidney Dis. 56, 57\u201368 (2010).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2013182_CR59","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1038\/ki.2008.644","volume":"75","author":"CM Giachelli","year":"2009","unstructured":"Giachelli, C. M. The emerging role of phosphate in vascular calcification. Kidney Int. 75, 890\u2013897 (2009).","journal-title":"Kidney Int."},{"key":"BFnrneph2013182_CR60","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1161\/CIRCRESAHA.110.234914","volume":"109","author":"CM Shanahan","year":"2011","unstructured":"Shanahan, C. M., Crouthamel, M. H., Kapustin, A. & Giachelli, C. M. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ. Res. 109, 697\u2013711 (2011).","journal-title":"Circ. Res."},{"key":"BFnrneph2013182_CR61","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/0883-2897(89)90143-8","volume":"16","author":"EB Silberstein","year":"1989","unstructured":"Silberstein, E. B., Clark, R. A. & DeLong, S. Clinical and radiographic correlates of femoral artery visualization on bone scan. Int. J. Rad. Appl. Instrum. B 16, 709\u2013713 (1989).","journal-title":"Int. J. Rad. Appl. Instrum. B"},{"key":"BFnrneph2013182_CR62","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ejphar.2006.12.006","volume":"558","author":"K Tamura","year":"2007","unstructured":"Tamura, K. et al. Prevention of aortic calcification by etidronate in the renal failure rat model. Eur. J. Pharmacol. 558, 159\u2013166 (2007).","journal-title":"Eur. J. Pharmacol."},{"key":"BFnrneph2013182_CR63","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2165\/00044011-200626040-00006","volume":"26","author":"T Ariyoshi","year":"2006","unstructured":"Ariyoshi, T., Eishi, K., Sakamoto, I., Matsukuma, S. & Odate, T. Effect of etidronic acid on arterial calcification in dialysis patients. Clin. Drug Investig. 26, 215\u2013222 (2006).","journal-title":"Clin. Drug Investig."},{"key":"BFnrneph2013182_CR64","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s00198-004-1662-x","volume":"16","author":"LB Tank\u00f3","year":"2005","unstructured":"Tank\u00f3, L. B., Qin, G., Alexandersen, P., Bagger, Y. Z. & Christiansen, C. Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women. Osteoporos. Int. 16, 184\u2013190 (2005).","journal-title":"Osteoporos. Int."},{"key":"BFnrneph2013182_CR65","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/S1076-6332(03)80516-0","volume":"9","author":"JA Hill","year":"2002","unstructured":"Hill, J. A. et al. Progression of coronary artery calcification in patients taking alendronate for osteoporosis. Acad. Radiol. 9, 1148\u20131152 (2002).","journal-title":"Acad. Radiol."},{"key":"BFnrneph2013182_CR66","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1001\/jama.283.11.1424","volume":"283","author":"ST Harris","year":"2000","unstructured":"Harris, S. T. Bisphosphonate therapy and vascular calcification. JAMA 283, 1424\u20131425 (2000).","journal-title":"JAMA"},{"key":"BFnrneph2013182_CR67","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black, D. M. et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 356, 1809\u20131822 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneph2013182_CR68","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1359\/jbmr.071024","volume":"23","author":"JT Schousboe","year":"2008","unstructured":"Schousboe, J. T. et al. Abdominal aortic calcification detected on lateral spine images from a bone densitometer predicts incident myocardial infarction or stroke in older women. J. Bone Miner. Res. 23, 409\u2013416 (2008).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrneph2013182_CR69","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00198-012-2213-5","volume":"24","author":"JH Kang","year":"2013","unstructured":"Kang, J. H., Keller, J. J. & Lin, H. C. Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study. Osteoporos. Int. 24, 271\u2013277 (2013).","journal-title":"Osteoporos. Int."},{"key":"BFnrneph2013182_CR70","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.clinthera.2011.07.012","volume":"33","author":"PY Lu","year":"2011","unstructured":"Lu, P. Y., Hsieh, C. F., Tsai, Y. W. & Huang, W. F. Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate. Clin. Ther. 33, 1173\u20131179 (2011).","journal-title":"Clin. Ther."},{"key":"BFnrneph2013182_CR71","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s00223-011-9549-2","volume":"90","author":"P Vestergaard","year":"2012","unstructured":"Vestergaard, P. Acute myocardial infarction and atherosclerosis of the coronary arteries in patients treated with drugs against osteoporosis: calcium in the vessels and not the bones? Calcif. Tissue Int. 90, 22\u201329 (2012).","journal-title":"Calcif. Tissue Int."},{"key":"BFnrneph2013182_CR72","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/jbmr.1792","volume":"28","author":"F Wolfe","year":"2013","unstructured":"Wolfe, F. et al. Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis. J. Bone Miner. Res. 28, 984\u2013991 (2013).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrneph2013182_CR73","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1053\/j.ajkd.2011.11.037","volume":"59","author":"JE Hartle","year":"2012","unstructured":"Hartle, J. E. et al. Bisphosphonate therapy, death, and cardiovascular events among female patients with CKD: a retrospective cohort study. Am. J. Kidney Dis. 59, 636\u2013644 (2012).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2013182_CR74","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1097\/01.ASN.0000129337.50739.48","volume":"15","author":"GM London","year":"2004","unstructured":"London, G. M. et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J. Am. Soc. Nephrol. 15, 1943\u20131951 (2004).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2013182_CR75","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1359\/jbmr.090735","volume":"25","author":"C Tomiyama","year":"2010","unstructured":"Tomiyama, C. et al. Coronary calcification is associated with lower bone formation rate in CKD patients not yet in dialysis treatment. J. Bone Miner. Res. 25, 499\u2013504 (2010).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrneph2013182_CR76","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1053\/j.ajkd.2008.06.024","volume":"52","author":"DV Barreto","year":"2008","unstructured":"Barreto, D. V. et al. Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study. Am. J. Kidney Dis. 52, 1139\u20131150 (2008).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2013182_CR77","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1093\/ndt\/gfq491","volume":"26","author":"G Asci","year":"2011","unstructured":"Asci, G. et al. The link between bone and coronary calcifications in CKD-5 patients on haemodialysis. Nephrol. Dial. Transplant. 26, 1010\u20131015 (2011).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2013182_CR78","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.1093\/ndt\/gfr591","volume":"26","author":"JB Cannata-Andia","year":"2011","unstructured":"Cannata-Andia, J. B., Roman-Garcia, P. & Hruska, K. The connections between vascular calcification and bone health. Nephrol. Dial. Transplant. 26, 3429\u20133436 (2011).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2013182_CR79","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/ki.2012.253","volume":"82","author":"SM Ott","year":"2012","unstructured":"Ott, S. M. Bisphosphonate safety and efficacy in chronic kidney disease. Kidney Int. 82, 833\u2013835 (2012).","journal-title":"Kidney Int."},{"key":"BFnrneph2013182_CR80","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000316708","volume":"33","author":"D Cejka","year":"2010","unstructured":"Cejka, D., Kodras, K., Bader, T. & Haas, M. Treatment of hemodialysis-associated adynamic bone disease with teriparatide (PTH(1\u201334): a pilot study. Kidney Blood Press. Res. 33, 221\u2013226 (2010).","journal-title":"Kidney Blood Press. Res."},{"key":"BFnrneph2013182_CR81","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1002\/jbmr.149","volume":"25","author":"I Reid","year":"2010","unstructured":"Reid, I. et al. Effects of denosumab on bone histomorphometry: the freedom and stand studies. J. Bone Miner. Res. 25, 2256\u20132265 (2010).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrneph2013182_CR82","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone, H. G. et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J. Clin. Endocrinol. Metab. 96, 972\u2013980 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrneph2013182_CR83","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/jbmr.403","volume":"26","author":"SA Jamal","year":"2011","unstructured":"Jamal, S. A. et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J. Bone Miner. Res. 26, 1829\u20131835 (2011).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrneph2013182_CR84","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1002\/jbmr.1613","volume":"27","author":"GA Block","year":"2012","unstructured":"Block, G. A., Bone, H. G., Fang, L., Lee, E. & Padhi, D. A single-dose study of denosumab in patients with various degrees of renal impairment. J. Bone Miner. Res. 27, 1471\u20131479 (2012).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrneph2013182_CR85","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1053\/j.ajkd.2012.06.019","volume":"60","author":"BB McCormick","year":"2012","unstructured":"McCormick, B. B., Davis, J. & Burns, K. D. Severe hypocalcemia following denosumab injection in a hemodialysis patient. Am. J. Kidney Dis. 60, 626\u2013628 (2012).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2013182_CR86","doi-asserted-by":"crossref","first-page":"756.e1","DOI":"10.1016\/j.ajem.2012.11.011","volume":"31","author":"P Ungprasert","year":"2013","unstructured":"Ungprasert, P., Cheungpasitporn, W., Srivali, N., Kittanamongkolchai, W. & Bischof, E. F. Life-threatening hypocalcemia associated with denosumab in a patient with moderate renal insufficiency. Am. J. Emerg. Med. 31, 756.e1\u2013756.e2 (2013).","journal-title":"Am. J. Emerg. Med."},{"key":"BFnrneph2013182_CR87","doi-asserted-by":"publisher","unstructured":"Qi, W. X., Tang, L. N., He, A. N., Yao, Y. & Shen, Z. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int. J. Clin. Oncol. http:\/\/dx.doi.org\/10.1007\/s10147-013-0561-0566 .","DOI":"10.1007\/s10147-013-0561-0566"},{"key":"BFnrneph2013182_CR88","doi-asserted-by":"publisher","first-page":"531","DOI":"10.4140\/TCP.n.2008.531","volume":"23","author":"S Lam","year":"2008","unstructured":"Lam, S. & Zouzias, K. Strontium ranelate for the management of osteoporosis. Consult. Pharm. 23, 531\u2013537 (2008).","journal-title":"Consult. Pharm."},{"key":"BFnrneph2013182_CR89","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1111\/j.1523-1755.2005.00156.x","volume":"67","author":"L Oste","year":"2005","unstructured":"Oste, L. et al. Time-evolution and reversibility of strontium-induced osteomalacia in chronic renal failure rats. Kidney Int. 67, 920\u2013930 (2005).","journal-title":"Kidney Int."},{"key":"BFnrneph2013182_CR90","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1002\/jbmr.337","volume":"26","author":"Q Yang","year":"2011","unstructured":"Yang, Q., Jian, J., Abramson, S. B. & Huang, X. Inhibitory effects of iron on bone morphogenetic protein 2-induced osteoblastogenesis. J. Bone Miner. Res. 26, 1188\u20131196 (2011).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrneph2013182_CR91","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1046\/j.1523-1755.2003.00809.x","volume":"63","author":"I Schrooten","year":"2003","unstructured":"Schrooten, I. et al. Dose-dependent effects of strontium on bone of chronic renal failure rats. Kidney Int. 63, 927\u2013935 (2003).","journal-title":"Kidney Int."},{"key":"BFnrneph2013182_CR92","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1046\/j.1523-1755.2000.00938.x","volume":"57","author":"PC D'Haese","year":"2000","unstructured":"D'Haese, P. C. et al. Increased bone strontium levels in hemodialysis patients with osteomalacia. Kidney Int. 57, 1107\u20131114 (2000).","journal-title":"Kidney Int."},{"issue":"Suppl. 2","key":"BFnrneph2013182_CR93","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/ndt\/17.suppl_2.30","volume":"17","author":"M Cohen-Solal","year":"2002","unstructured":"Cohen-Solal, M. Strontium overload and toxicity: impact on renal osteodystrophy. Nephrol. Dial. Transplant. 17 (Suppl. 2), 30\u201334 (2002).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2013182_CR94","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1530\/EJE-11-0415","volume":"165","author":"A Doublier","year":"2011","unstructured":"Doublier, A. et al. Distribution of strontium and mineralization in iliac bone biopsies from osteoporotic women treated long-term with strontium ranelate. Eur. J. Endocrinol. 165, 469\u2013476 (2011).","journal-title":"Eur. J. Endocrinol."},{"key":"BFnrneph2013182_CR95","doi-asserted-by":"publisher","unstructured":"O'Donnell, S., Cranney, A., Wells, G. A., Adachi, J. D. & Reginster, J Y. Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database of Systematic Reviews, Issue 3. Art. No.: CD005326. http:\/\/dx.doi.org\/10.1002\/14651858.CD005326.pub2 .","DOI":"10.1002\/14651858.CD005326.pub2"},{"key":"BFnrneph2013182_CR96","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1002\/jbmr.1630","volume":"27","author":"Y Sabbagh","year":"2012","unstructured":"Sabbagh, Y. et al. Repression of osteocyte Wnt\/beta-catenin signaling is an early event in the progression of renal osteodystrophy. J. Bone Miner. Res. 27, 1757\u20131772 (2012).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrneph2013182_CR97","doi-asserted-by":"crossref","first-page":"691","DOI":"10.7326\/0003-4819-158-9-201305070-00603","volume":"158","author":"VA Moyer","year":"2013","unstructured":"Moyer, V. A. Vitamin D and calcium supplementation to prevent fractures in adults: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 158, 691\u2013696 (2013).","journal-title":"Ann. Intern. Med."},{"key":"BFnrneph2013182_CR98","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S0272-6386(12)80356-8","volume":"17","author":"JW Coburn","year":"1991","unstructured":"Coburn, J. W., Mischel, M. G., Goodman, W. G. & Salusky, I. B. Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide. Am. J. Kidney Dis. 17, 708\u2013711 (1991).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2013182_CR99","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1097\/MNH.0b013e3283470450","volume":"20","author":"RN Moorthi","year":"2011","unstructured":"Moorthi, R. N., Kandula, P. & Moe, S. M. Optimal vitamin D, calcitriol, and vitamin D analog replacement in chronic kidney disease: to D or not to D: that is the question. Curr. Opin. Nephrol. Hypertens. 20, 354\u2013359 (2011).","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"BFnrneph2013182_CR100","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1038\/sj.ki.5001868","volume":"70","author":"F Tentori","year":"2006","unstructured":"Tentori, F. et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 70, 1858\u20131865 (2006).","journal-title":"Kidney Int."},{"key":"BFnrneph2013182_CR101","unstructured":"Institute of Medicine Standing Committee. Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride (National Academies Press, 1997)."},{"key":"BFnrneph2013182_CR102","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1093\/ndt\/gfr620","volume":"27","author":"SL West","year":"2012","unstructured":"West, S. L., Jamal, S. A. & Lok, C. E. Tests of neuromuscular function are associated with fractures in patients with chronic kidney disease. Nephrol. Dial. Transplant. 27, 2384\u20132388 (2012).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2013182_CR103","doi-asserted-by":"publisher","unstructured":"Howe, T. E. et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database of Systematic Reviews, Issue 7. Art. No.: CD000333. http:\/\/dx.doi.org\/10.1002\/14651858.CD000333.pub2 .","DOI":"10.1002\/14651858.CD000333.pub2"},{"key":"BFnrneph2013182_CR104","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1093\/ndt\/gfm778","volume":"23","author":"M Li","year":"2008","unstructured":"Li, M., Tomlinson, G., Naglie, G., Cook, W. L. & Jassal, S. V. Geriatric comorbidities, such as falls, confer an independent mortality risk to elderly dialysis patients. Nephrol. Dial. Transplant. 23, 1396\u20131400 (2008).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph2013182_CR105","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1053\/j.ajkd.2004.09.027","volume":"45","author":"C Desmet","year":"2005","unstructured":"Desmet, C., Beguin, C., Swine, C. & Jadoul, M. Falls in hemodialysis patients: prospective study of incidence, risk factors, and complications. Am. J. Kidney Dis. 45, 148\u2013153 (2005).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2013182_CR106","doi-asserted-by":"publisher","first-page":"5866","DOI":"10.1074\/jbc.M705092200","volume":"283","author":"AG Robling","year":"2008","unstructured":"Robling, A. G. et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of sost\/sclerostin. J. Biol. Chem. 283, 5866\u20135875 (2008).","journal-title":"J. Biol. Chem."},{"key":"BFnrneph2013182_CR107","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.bone.2005.01.007","volume":"36","author":"A Jackson","year":"2005","unstructured":"Jackson, A. et al. Gene array analysis of Wnt-regulated genes in C3H10T1\/2 cells. Bone 36, 585\u2013598 (2005).","journal-title":"Bone"},{"key":"BFnrneph2013182_CR108","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1002\/jbmr.474","volume":"26","author":"AH van Lierop","year":"2011","unstructured":"van Lierop, A. H. et al. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J. Bone Miner. Res. 26, 2804\u20132811 (2011).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrneph2013182_CR109","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00223-012-9595-4","volume":"90","author":"S Thambiah","year":"2012","unstructured":"Thambiah, S. et al. Circulating sclerostin and dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif. Tissue Int. 90, 473\u2013480 (2012).","journal-title":"Calcif. Tissue Int."},{"key":"BFnrneph2013182_CR110","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1002\/jbmr.345","volume":"26","author":"GJ Atkins","year":"2011","unstructured":"Atkins, G. J. et al. Sclerostin is a locally acting regulator of late-osteoblast\/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. J. Bone Miner. Res. 26, 1425\u20131436 (2011).","journal-title":"J. Bone Miner. Res."},{"key":"BFnrneph2013182_CR111","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.bone.2011.06.025","volume":"49","author":"Y Rhee","year":"2011","unstructured":"Rhee, Y. et al. Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone 49, 636\u2013643 (2011).","journal-title":"Bone"},{"key":"BFnrneph2013182_CR112","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1073\/pnas.1221255110","volume":"110","author":"ZC Ryan","year":"2013","unstructured":"Ryan, Z. C. et al. Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium. Proc. Natl Acad. Sci. USA 110, 6199\u20136204 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneph2013182_CR113","unstructured":"McClung, M. R., Grauer, A., Boonen, S. & Brown, J. P. Inhibition of sclerostin with AMG 785 in postmenopausal women with low bone mineral density: phase 2 trial results [abstract 1052, online]. http:\/\/www.asbmr.org\/Meetings\/AnnualMeeting\/AbstractDetail.aspx?aid=9fa27a06-d9b5-4429-a95f-517048985173 (2012)."},{"key":"BFnrneph2013182_CR114","unstructured":"Hudson, B., Loots, G., Hum, N. & Thomas, C. SOST inhibits prostate cancer invasion [abstract 1086, online]. http:\/\/www.asbmr.org\/Meetings\/AnnualMeeting\/AbstractDetail.aspx?aid=1ae8843c-167d-4945-9cc8-cc8398018b96 (2012)."},{"key":"BFnrneph2013182_CR115","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/jcb.22779","volume":"111","author":"V Shalhoub","year":"2010","unstructured":"Shalhoub, V. et al. Chondro\/osteoblastic and cardiovascular gene modulation in human artery smooth muscle cells that calcify in the presence of phosphate and calcitriol or paricalcitol. J. Cell Biochem. 111, 911\u2013921 (2010).","journal-title":"J. Cell Biochem."},{"key":"BFnrneph2013182_CR116","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.bone.2009.09.006","volume":"46","author":"P Roman-Garcia","year":"2010","unstructured":"Roman-Garcia, P. et al. High phosphorus diet induces vascular calcification, a related decrease in bone mass and changes in the aortic gene expression. Bone 46, 121\u2013128 (2010).","journal-title":"Bone"},{"key":"BFnrneph2013182_CR117","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1038\/ki.2011.255","volume":"80","author":"D Wang","year":"2011","unstructured":"Wang, D., Dai, C., Li, Y. & Liu, Y. Canonical Wnt\/beta-catenin signaling mediates transforming growth factor-beta1-driven podocyte injury and proteinuria. Kidney Int. 80, 1159\u20131169 (2011).","journal-title":"Kidney Int."},{"key":"BFnrneph2013182_CR118","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1681\/ASN.2008060566","volume":"20","author":"W He","year":"2009","unstructured":"He, W. et al. Wnt\/beta-catenin signaling promotes renal interstitial fibrosis. J. Am. Soc. Nephrol. 20, 765\u2013776 (2009).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph2013182_CR119","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jacc.2012.03.040","volume":"60","author":"JH Ix","year":"2012","unstructured":"Ix, J. H. et al. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J. Am. Coll. Cardiol. 60, 200\u2013207 (2012).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFnrneph2013182_CR120","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1053\/j.ajkd.2011.09.019","volume":"59","author":"A Young","year":"2011","unstructured":"Young, A. et al. Bone and mineral metabolism and fibroblast growth factor 23 levels after kidney donation. Am. J. Kidney Dis. 59, 761\u2013769 (2011).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph2013182_CR121","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s00467-011-1870-5","volume":"26","author":"E Siomou","year":"2011","unstructured":"Siomou, E. et al. Serum osteoprotegerin, RANKL and fibroblast growth factor-23 in children with chronic kidney disease. Pediatr. Nephrol. 26, 1105\u20131114 (2011).","journal-title":"Pediatr. Nephrol."},{"key":"BFnrneph2013182_CR122","unstructured":"FDA. Drugs@FDA [online] ."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2013.182.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2013.182","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2013.182.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T15:56:41Z","timestamp":1746028601000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2013.182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,8]]},"references-count":122,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["BFnrneph2013182"],"URL":"https:\/\/doi.org\/10.1038\/nrneph.2013.182","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,8]]}}}